Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
Indomethacin showed no clear difference in all‐cause neonatal mortality before hospital discharge compared with placebo or control (moderate certainty).
Indomethacin showed no clear difference in proportion of infants requiring surgical ligation of PDA compared with placebo or control (moderate certainty).
Indomethacin showed no clear difference in NEC (≥ Bell stage 2) compared with placebo or control (low certainty).
Indomethacin showed no clear difference in mucocutaneous or gastrointestinal bleeding compared with placebo or control (low certainty).
Rapid susceptibility methods showed no clear difference in mortality compared with standard methods versus placebo (low certainty).
Rapid susceptibility methods showed no clear difference in mortality (subgroup genotypic) compared with standard methods versus placebo (low certainty).
Rapid susceptibility methods showed no clear difference in mortality (subgroup phenotypic) compared with standard methods versus placebo (low certainty).
Rapid susceptibility methods showed no clear difference in mortality (with stewardship) compared with standard methods versus placebo (low certainty).
Rapid susceptibility methods showed no clear difference in mortality (without stewardship) compared with standard methods versus placebo (low certainty).